Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Costs and Benefits of Covid-19 Lockdowns in New Zealand

Martin Lally
doi: https://doi.org/10.1101/2021.07.15.21260606
Martin Lally
Capital Financial Consultants Ltd
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lallym@xtra.co.nz
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

This paper considers the costs and benefits of New Zealand’s Covid-19 nation-wide lockdown strategy relative to pursuit of a mitigation strategy in March 2020. Using data available up to 28 June 2021, the estimated additional deaths from a mitigation strategy are 1,750 to 4,600, implying a Cost per Quality Adjusted Life Year saved by locking down in March 2020 of at least 13 times the generally employed threshold figure of $62,000 for health interventions in New Zealand; the lockdowns do not then seem to have been justified by reference to the standard benchmark. Using only data available to the New Zealand government in March 2020, the ratio is similar and therefore the same conclusion holds that the nation-wide lockdown strategy was not warranted. Looking forwards from 28 June 2021, if a new outbreak occurs that cannot be suppressed without a nation-wide lockdown, the death toll from adopting a mitigation strategy at this point would be even less than had it done so in March 2020, due to the vaccination campaign and because the period over which the virus would then inflict casualties would now be much less than the period from March 2020; this would favour a mitigation policy even more strongly than in March 2020. This approach of assessing the savings in quality adjusted life years and comparing them to a standard benchmark figure ensures that all quality adjusted life years saved by various health interventions are treated equally, which accords with the ethical principle of equity across people.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

No human subjects used or referred to in the study.

Funding Statement

No funding of any kind received.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not Applicable. No human subjects used or referred in in the analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The helpful comments of Glenn Boyle, Amanda Breton, Paul Calcott, Eric Crampton, John Gibson, Dave Heatley, Shaun Hendy, Mark Johnson, Michael Reddell, Jack Robles, and Adrian Slack, and those of participants in a seminar at Victoria University on 18 September, are gratefully acknowledged. Agreement with the conclusions is not implied and should not be inferred.

Data Availability

All data referred to in the paper is publicly available at the weblinks provided in the paper.

https://www.worldometers.info/coronavirus/

https://covidtracker.bsg.ox.ac.uk/

https://www.euromomo.eu/graphs-and-maps#excess-mortality

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Costs and Benefits of Covid-19 Lockdowns in New Zealand
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Costs and Benefits of Covid-19 Lockdowns in New Zealand
Martin Lally
medRxiv 2021.07.15.21260606; doi: https://doi.org/10.1101/2021.07.15.21260606
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The Costs and Benefits of Covid-19 Lockdowns in New Zealand
Martin Lally
medRxiv 2021.07.15.21260606; doi: https://doi.org/10.1101/2021.07.15.21260606

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (556)
  • Anesthesia (135)
  • Cardiovascular Medicine (1766)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (313)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (661)
  • Epidemiology (10807)
  • Forensic Medicine (8)
  • Gastroenterology (593)
  • Genetic and Genomic Medicine (2959)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1932)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (632)
  • Infectious Diseases (except HIV/AIDS) (12523)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2803)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1472)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5379)
  • Radiology and Imaging (1015)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)